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AN UPDATED ANALYSIS OF MICROVWVE HYPERTHERMIA AT 
2450 MEGAHERTZ AND 915 MEGAHERTZ FREQUENCIES. 
Kenneth E. Luk, M.D.* 
Cl a i r e Zellerbach Saroni Tumor I n s t i t u t e of Mount 
Zion H o s p i t a l & Medical Center, and the Departm.ent 
of Radiation Oncology, U n i v e r s i t y of C a l i f o r n i a , 
Ean Francisco, C a l i f o r n i a . 
Microwave hypertherm.ia a t frequencies of 2450 megahertz and 915 mega-
hertz was used t o t r e a t s u p e r f i c i a l measurable tumors of d i f f e r e n t h i s t o -
pathologies at various s i t e s . P a t i e n t tolerance of temperatures up t o 
42.5° C. v/as observed. 59 courses of treatments were given t o 47 p a t i e n t s 
Hyperthermia alone at 40 t o 42.5° C. v/as not e f f e c t i v e t o o b t a i n tumor 
response. However, hyperthermia and r a d i a t i o n (to 2700 rads i n 9 f r a c -
t i o n s over three weeks) produced complete and p a r t i a l responses i n three-
f o u r t h s of the treatm.ent courses. The combination of hyperthermia and 
chemotherapy m.ay have great p o t e n t i a l . Confirmation of these c l i n i c a l 
impressions w i l l depend on a much l a r g e r s e r i e s of p a t i e n t data. P a r t i -
c i p a t i o n i n cooperative studies such as the Hyperthermia Study Group of 
Radiation Therapy Oncology Group i s urged. 
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INTRODUCTION 
Encouraged by numerous promising r e p o r t s of the t u m o r i c i d a l e f f e c t s 
of hypertherm.ia i n v i v o and i n v i t r o (1,2,3,4), a c l i n i c a l hypertherm.ia 
program was s t a r t e d a t the C l a i r e Zellerbach Saroni Tumor I n s t i t u t e of 
Mount Zion H o s p i t a l and Medical Center i n December, 1976. This paper pre-
sents an updated analysis of r e s u l t s of treatment of 47 cancer p a t i e n t s 
w i t h 2450 megahertz and 915 megahertz frequencies microwave hyperthermia. 
METHODS AND MATERIALS 
Instrumentations 
24 50 megahertz microwave was generated by a diathermy u n i t manu-
fa c t u r e d by Burdick Corporation (Model MW/200), and was broadcast by 
Burdick Type B or E a p p l i c a t o r s . Heat i n d u c t i o n can be achieved t o reach 
t i s s u e s about one centimeter i n depth and t h e r e f o r e only s u p e r f i c i a l 
lesions can be t r e a t e d by t h i s equipm.ent. The a p p l i c a t o r s can be e i t h e r 
an 8 cm diameter c i r c l e or 14 x 17 cm rec t a n g l e . 
A v a r i a b l e frequency (400 MHz - 1000 MHz) MCL Model 15122 r a d i o -
frequency generator was used t o produce 915 m.egahertz microwave. A 
d i e l e c t r i c - f i l l e d a p p l i c a t o r measuring 8 x 8 cm v/as constructed to 
d e l i v e r t h i s microwave r a d i a t i o n and e f f e c t i v e heating can be achieved i n 
tiss u e s up t o 4.5 cm i n depth. 
*This work is done with partial support from Mount Zion Hospital General Research Fund, 
Kenneth H. Luk, M. D. Cancer Research Fund, and the Radiation Therapy Oncology Group. 
Dr. Luk is a recipient of an American Cancer Society Junior Faculty Clinical Fellowship. 
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Thermometry 
Tumor t i s s u e s temperature measurements were made by i n s e r t i n g a 
Yellow Springs Model 524 t h e r m i s t o r needle a t the desired depth, w i t h 
the needle p o s i t i o n e d c a r e f u l l y at r i g h t angles to the e l e c t r i c f i e l d t o 
minimize heating perturbance. This needle was l e f t i n s i t u f o r c o n t i n -
uous temperature m o n i t o r i n g , w i t h measurements being made a t 5 minute 
i n t e r v a l s . Skin temperature was also p e r i o d i c a l l y obtained. 
Skin c o o l i n g was not performed f o r the p a t i e n t s included i n t h i s 
r e p o r t , but was u t i l i z e d w i t h subsequent p a t i e n t treatments. 
The prescribed tumor temperature of 4 2.5° C. was not alv/ays achiev-
able, due t o many f a c t o r s i n c l u d i n g heat conduction by l o c a l v a s c u l a t u r e , 
and p a t i e n t i n t o l e r a n c e . 
Treatment Schedule 
Most p a t i e n t s were t r e a t e d three times a week on Mondays, Wednesdays 
and Fridays f o r 2 or 3 weeks. Thus, these p a t i e n t s received e i t h e r s i x 
or nine treatments of hyperthermia. Some p a t i e n t s were t r e a t e d twice a 
week on a Monday-Thursday, or Tuesday-Friday schedule, however. These 
schedules were devised because of i n v i t r o observation of the phenomenon 
of "thermotolerance" (5,6). 
P a t i e n t s who received combined hyperthermia and r a d i a t i o n had the 
hyperthermia given immediately a f t e r r a d i a t i o n , which was u s u a l l y elec-
t r o n beam of the appropriate energy f o r the depth of the tumor at 30 0 
rads per f r a c t i o n . Chemotherapeutic drugs were given (Bleomycin i n t r a -
venously f o r head and neck cancers) one t o two hours p r i o r t o l o c a l 
hyperthermia f o r the few p a t i e n t s on the combined chemotherapy and 
hyperthermia p r o t o c o l . 
P a t i e n t Population 
Pa t i e n t s accepted f o r t h i s hyperthermia treatment program had observ-
able and measurable r e c u r r e n t or m e t a s t a t i c tumors, and had f a i l e d con-
v e n t i o n a l cancer treatments. I o n i z i n g r a d i a t i o n was added t o hyperthermia 
when previous radiotherapy d i d not exceed normal t i s s u e t o l e r a n c e , and 
t h i s u s u a l l y meant the dose equivalence of about 6000 rads i n 6 weeks. 
Bleomycin i n 5 mg bolus was given one t o two hours before hyper-
thermia i n head and neck cancers. The dosage was purposely chosen t o be 
low so as not t o mask or a f f e c t s t r o n g l y any e f f i c a c y of hyperthermia. 
The p a t i e n t s were e n r o l l e d i n one of four programs: (1) Hyper-
thermia o n l y , (2) Hyperthermia and radiotherapy, (3) Hyperthermia and 
chemotherapy, and (4) Hyperthermia plus radiotherapy and chemotherapy. 
To date, most p a t i e n t s received e i t h e r hyperthermia alone, or hyper-
thermia and radiotherapy. 
72 
Method of Evaluation 
The size of a t r e a t e d l e s i o n was measured w i t h a c a l i p e r i n at l e a s t 
two dimensions, and the depth of a tumor was measured whenever p o s s i b l e . 
Measurements were made before, d u r i n g and a f t e r a treatment course, and 
at follow-up examinations of frequent i n t e r v a l s . P o l a r o i d c o l o r photo-
graphs were obtained t o ensure documentation, and notes were d e t a i l e d t o 
describe observations of tumor regression, normal t i s s u e e f f e c t s and 
p a t i e n t s t a t u s . 
Since t h i s group of p a t i e n t s had advanced cancers, s u r v i v a l a f t e r 
treatment was s h o r t . Local tumor response became the only evaluable 
parameter. Treatment responses were r a t e d as complete (CR = 100% regres-
sion) , p a r t i a l (PR> 50% regression) and no response (NRi. 50% r e g r e s s i o n ) . 
RESULTS 
Fi f t y - s e v e n p a t i e n t s received hyperthermia, but ten p a t i e n t s were 
not evaluable due t o e a r l y deaths, inadequate measurable l e s i o n , pre-
mature s u r g i c a l e x c i s i o n , and l o s t t o f o l l o w - u p . The d i s t r i b u t i o n of 
the d i f f e r e n t types of tumors t r e a t e d by hyperthermia was not representa-
t i v e of the cases t r e a t e d w i t h r a d i a t i o n therapy i n our department. Most 
of the p a t i e n t s t r e a t e d w i t h 2450 megahertz microwave had chest w a l l 
recurrence of breast cancer a f t e r mastectomy, radiotherapy and chemo-
therapy or hormonal therapy. On the other hand, many p a t i e n t s t r e a t e d 
w i t h 915 megahertz microwave had nodal recurrences i n the neck or the 
g r o i n i n p r e v i o u s l y i r r a d i a t e d areas. 
TABLE I 
2450 MHz 915 MHz 
No. of No. of 
patients Histopathology patients Histopathology 
26 Breast carcinoma 2 Renal carcinoma 
1 Breast sarcoma 1 Nasopharyngeal carcinoma 
1 Chondrosarcoma 2 Colonic carcinoma 
1 H i s t i o c y t i c lymphoma 1 Rectal carcinoma 
1 Rectal carcinoma 2 Breast carcinoma 
1 Vaginal carcinoma 
1 Floor-of-Mouth carcinoma 
3 Laryngeal carcinoma 
1 Melanoma 
TOTAL = 31 TOTAL = 16 
Histopathology of lesions treated by 2450 megahertz and 915 megahertz 
microwave hyperthermia. 
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Some p a t i e n t s were t r e a t e d w i t h hyperthermia t o more than one s i t e . 
A few s i t e s received two serie s of treatments of hyperthermia w i t h an 
i n t e r v a l of time between two treatment courses. Altogether there were 
40 courses given w i t h 2450 megahertz and 19 courses w i t h 915 megahertz 
microwave. 
Hyperthermia Alone vs. Hyperthermia and Radiation 
At the tem.perature range of 40 - 4 2.5° C, hyperthermia alone d i d not 
seem to be e f f e c t i v e i n inducing tumor regression. When hyperthermia was 
given a f t e r low dose r a d i a t i o n (mostly 1800 rads/6 f r a c t i o n s t o 2700 rads/ 
9 f r a c t i o n s ) , a higher response r a t e was observed. A comparison of t r e a t -
ment response r a t e i s made between hyperthermia alone and hyperthermia 
plus radiotherapy i n Table 2. Since most of these p a t i e n t s died w i t h i n 
a few months a f t e r hyperthermia, a study of the d u r a t i o n of treatment 
responses would not be meaningful. 
TABLE I I 
Primary Site Hyperthermia alone Hyperthermia + Radiation 
CR PR NR CR PR NR 
Adenocarcinoma 
Breast 
Rectum 
Colon 
Ovary 
Kidney 
1 5 
1 
1 
10 13 5 
1 1 
2 
3 
Squamous c e l l carcinoma 
Head and Neck 
Lung 
Vagina 
2 
1 
2 1 1 
1 
Sarcoma 
Extremity 
Breast 
1 
1 
Melanoma 
Extremity 1 
Lymphoma 
Lymphatics 1 
TOTAL 1 2 8 15 18 11 
Local tumor.response to treatment with hyperthermia alone and hyperthermia 
plus radiation. CR = complete response,^^R = p a r t i a l r e s p o n s e n o response, 
Renal c e l l carcinoma and sarcoma seemed t o have a lower tumor 
response r a t e . The one case of melanoma achieved near complete regres-
sion a f t e r hyperthermia and r a d i a t i o n , but there was r e s i d u a l i n d u r a -
t i o n on c l i n i c a l p a l p a t i o n . 
Hyperthermia and Chemotherapy 
There were only f o u r cases of combined treatm.ents of hyperthermia 
and chemotherapy. As mentioned p r e v i o u s l y , the chemotherapy consisted 
of Bleomycin 5 mg i n t r a v e n o u s l y one t o two hours p r i o r t o hyperthermia. 
I n f a c t , three of the four p a t i e n t s also received 2700 rads i n 9 f r a c -
t i o n s w i t h e l e c t r o n beam. A l l four cases were squamous c e l l carcinoma 
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r e c u r r e n t i n the neck from nasopharyngeal and l a r y n g e a l prim.ary tumors. 
One p a t i e n t who received hypertherm.ia and bleomycin experienced a complete 
response f o r two months, but f a i l e d a t the edge of the treatment area. 
Two p a t i e n t s who received hyperthermia, bleomycin and r a d i a t i o n probably 
had complete c o n t r o l of disease. One died a c c i d e n t a l l y a t 12 months post 
treatment, and one continued t o be i n remission also at 12 months. The 
f o u r t h p a t i e n t had a p a r t i a l response and a t the present time was only 
three months post treatment. 
DISCUSSION 
To date we have found t h a t m.icrowave hypertherm.ia d e l i v e r e d i n the 
manner described has been g e n e r a l l y w e l l t o l e r a t e d by p a t i e n t s . Unfortu-
n a t e l y , hyperthermia alone t o a temperature of 42.5° C. has not been 
successful i n producing tumor responses. Higher temperatures m.ay be more 
e f f e c t i v e , but they may also be associated w i t h higher r a t e s of m o r b i d i t y . 
We found t h a t hyperthermia (42.5° C.) combined w i t h low-dose r a d i a -
t i o n has produced s i g n i f i c a n t tum.or responses. Our p a t i e n t s mostly had 
received previous radiotherapy and out of c o n s i d e r a t i o n of those p a t i e n t s ' 
s a f e t y , the dose of r a d i a t i o n w i t h hyperthermia was n e c e s s a r i l y lowered. 
I t may be poss i b l e t o achieve improved l o c a l c o n t r o l of bulky tumors by 
u t i l i z i n g hyperthermia and moderate doses of r a d i a t i o n . This concept i s 
appealing t o r a d i a t i o n o n c o l o g i s t s since l o c a l c o n t r o l of bulky, hypoxic 
tumors remain a r e a l challenge indeed. 
S i m i l a r l y , the p o s s i b i l i t y of improved l o c a l c o n t r o l w i t h hyperthermia 
and chemotherapy i s an e x c i t i n g one. Dramatic r e s u l t s were reported i n 
viv o and i n v i t r o (7,8,9). Our experience i n t h i s regard has been anec-
d o t a l . A l a r g e r s e r i e s of p a t i e n t s w i l l be r e q u i r e d i n order t o draw 
a conclusion. 
There are marked l i m i t a t i o n s i n c l i n i c a l a p p l i c a t i o n s of our present 
treatment system. The problems of accomplishing s a t i s f a c t o r y thermal d o s i -
metry i n conformance w i t h c l i n i c a l requirements has been addressed (10). 
We w i l l need t o make headway i n equipment research and development f o r 
b e t t e r heat d e l i v e r y and thermometry. C e r t a i n l y , there i s p l e n t y of room 
f o r i n n o v a t i v e designs and treatment techniques t o approach d i f f e r e n t 
anatomical l o c a t i o n s of cancerous tumors. 
At our present s t a t u s of knowledge of hyperthermia, the importance of 
sharing i n f o r m a t i o n and cooperative studies cannot be stressed enough. 
Much human and m a t e r i a l resources can be saved by a well-planned, con-
certed s c i e n t i f i c e f f o r t . P a r t i c i p a t i o n i n the Hyperthermia Study Group 
of the Radiation Oncology Group (RTOG) i s t h e r e f o r e worthwhile. 
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